Although our results were obtained in a relatively small, single arm study, gefitinib-treated patients whose tumours contained low CEN7/cell (or low EGFR/CEN7 gain or low EGFR gain), high PTEN loss, and high PIK3CA gain had significantly shorter PFS and OS than other patients. The gene discussed is EGFR; the disease is neoplasm.